Related Experiment Video
Updated: Jan 16, 2026
Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production
Published on: May 3, 2024
Scaling Down for Big Impact: Streamlined High-throughput Recombinant Adeno-associated Virus Production
Philip Ohland1, Miriam L Ferreiro2, Jatina Schumacher2
1Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Hoffmann-La Roche Ltd; Roche Pharma technical development Cell and Gene Therapy, Roche Innovation Center Munich, Roche Diagnostics GmbH; Center of Biomedical Education and Research - ZBAF, University of Witten/Herdecke.
Streamlined microscale and miniscale production methods accelerate gene therapy research by enabling rapid, high-throughput generation of recombinant adeno-associated viral (rAAV) vectors without extensive purification. This facilitates faster preclinical screening and therapeutic development.
Area of Science:
- Biotechnology
- Gene Therapy
- Molecular Biology
Background:
- Recombinant adeno-associated viral (rAAV) vectors are crucial for gene therapy.
- Current rAAV production and purification are time-consuming and labor-intensive bottlenecks.
- High-throughput, small-scale production offers a solution to accelerate research.
Purpose of the Study:
- To introduce streamlined microscale and miniscale rAAV production methods.
- To enable rapid generation of rAAV variants for preclinical screening.
- To optimize cell culture conditions and assess transgene biological activity.
Main Methods:
- Microscale production in 6-well plates using HEK 293T cells.
- Miniscale production in 24-well plates using suspension cells.
- Downstream analyses including vector genome titration, capsid titer, western blot, and transduction assays.
Main Results:
- Demonstrated efficient generation of rAAV vectors at micro and miniscale.
- Validated methods for optimizing cell culture and assessing transgene function.
- Compared semi-purified miniscale vectors with midiscale CsCl-purified vectors.
Conclusions:
- Streamlined methods accelerate the identification of lead gene therapy candidates.
- These workflows support iterative development in the gene therapy pipeline.
- The described protocols are readily implementable in research labs for enhanced efficiency.
